Peptides represent a billion-dollar market in the pharmaceutical industry, but they can generally only be taken as injections to avoid degradation by stomach enzymes. Scientists at EPFL have now developed a method to generate peptides that resist enzymatic degradation and can be taken orally.
Peptides are short chains of amino acids that occur in our body, in plants or bacteria to control diverse functions. Several peptides are used as drugs such as insulin, which controls the metabolism of sugar, and cyclosporine, which suppresses organ rejection after transplants. More than 40 peptides are already approved as drugs, generating revenues in the billions. There are several hundreds of peptide-based medications currently in clinical trials.
But almost none of these drug-peptides can be taken orally. Since peptides are an important part of food, the stomach and intestines harbor countless enzymes that can degrade them, meaning that most peptide-based medication do not survive the passage through the gastrointestinal tract.
Hope to generate more stable peptides came from “cyclic” peptides, whose ends are joined together by chemical bridges making them more stable than linear ones because their backbones are less flexible and thus harder to attack by enzymes. In 2018, the research group of Christian Heinis at EPFL developed a peptide format termed double-bridged peptides, where peptides are cyclized by two chemical bridges that provide even higher stability. Despite its success, most such peptides were not sufficiently stable to survive the enormous enzymatic pressure found in the gastrointestinal tract.
Now, Heinis’s group has developed a new method that identifies among billions of double-bridged peptides those that bind a disease target of interest and survive enzymes of the gastrointestinal tract. The method is published in Nature Biomedical Engineering, and involves three steps.
First, billions of genetically encoded random peptide sequences are cyclized by two chemical bridges that impose conformational constraints onto the peptides’ backbones so that they are more difficult to attack by enzymes.
Second, this library of peptides is exposed to enzymes from cow intestine to eliminate all those peptides that are not stable.
In the third and last step, the scientist dip target proteins into the pool of surviving peptides to fish out those that bind to the wanted disease target. “It’s a bit like searching a needle in a haystack, and this method makes this easy,” says Heinis.
With this method, the researchers have succeeded for the first time in evolving target-specific peptides that can resist breakdown in the gastrointestinal tract. For example, they gave mice a lead peptide that inhibits thrombin – an important anti-thrombosis target – in the form of a pill. The peptide remained intact in the stomach and intestines, and even though it reached the blood stream in rather small quantities, most of it remained fully intact across the entire gastrointestinal tract. This is a key step towards engineering oral peptide drugs.
Heinis’s group is now applying the new method to develop oral peptides that act directly on gastrointestinal targets, meaning that they don’t need to travel into the blood stream. “We are focusing on chronic inflammatory diseases of the gastrointestinal tract like Crohn’s disease and ulcerative colitis as well as bacterial infections,” says Heinis. “We have already succeeded in generating enzyme-resistant peptides against the interleukin-23 receptor, an important target of these diseases, which affect millions of patients worldwide without any oral drug available.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenueson May 12, 2021 at 3:32 am
First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients----New Drug Application Accepted for Revi ...
- Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal modelson May 11, 2021 at 1:15 pm
Here, the authors report bi-functional, wide tropic macrocycles that bind the influenza viral envelope protein hemagglutinin and inhibit virus infection by blocking adsorption and fusion and show ...
- Enteris BioPharma Completes Expansion of Manufacturing Facilityon May 11, 2021 at 7:13 am
Enteris’ capabilities include providing custom solutions for the formulation, development and manufacturing of solid oral doses for difficult to formulate BCS III and IV compounds, including peptides ...
- Natural products a rich source for novel antiviral compoundson May 10, 2021 at 8:34 pm
In a recent review in the journal Viruses, researchers look at natural products that can be identified as potential alternative antiviral agents. The reviewers discussed the antiviral activities of ...
- Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlightson May 10, 2021 at 1:30 pm
Announced Positive Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800 Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia Expected ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- North America To Lead The Global Peptide Based Cancer Therapeutics Market Insights 2017 to 2022on May 7, 2021 at 8:12 am
For detailed insights on enhancing your product footprint, request for a sample here- In terms of revenues, North America is expected to dominate the global peptide based cancer therapeutics market ...
- NeuroScientific Biopharmaceuticals (ASX:NSB) progresses ocular safety studieson May 4, 2021 at 10:00 pm
NeuroScientific Biopharmaceuticals (ASX:NSB) has completed two ocular pharmacokinetic (PK) and tissue distribution studies ahead of commencing phase one clinical studies in humans.
- ISSAR Pharma to out license its peptide-based New Chemical Entitieson May 4, 2021 at 9:25 pm
Hyderabad/IBNS: ISSAR Pharmaceuticals, a leading iIndian pharma company specialising in peptide technology and peptide drug innovation, announced they will license out their peptide-based New Chemical ...
- Peptide Drug Conjugate Market Size Clinical Trials Future 2026on May 4, 2021 at 9:30 am
To overcome these issues, many research groups have explored alternative approaches such as peptide-based drugs. In recent years peptides have emerged as the considerable therapeutic candidate ...
- Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients ...on May 4, 2021 at 8:00 am
Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary Chemotype Evolution (CE) technology to disco ...